• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

The Top 5 Biosimilars Articles for the Week of November 20


The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of November 20.


Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of November 20.

Number 5: The European Medicines Agency will move to Amsterdam, Netherlands, after European ministers voted on the agency’s post-Brexit relocation.

Number 4: A recently published case study shows that a non-medical switch to biosimilar infliximab was associated with a rapid loss of treatment response in multiple patients with Behçet's disease.

Number 3: Samsung Bioepis has been granted the first European marketing authorization for a trastuzumab biosimilar, referenced on Herceptin.

Number 2: Stacie Phan, president of the Biosimilars Forum, explains the critical need for US physicians to gain better education on biosimilar therapies.

Number 1: Swiss drug maker Roche has sued biosimilar developer Pfizer over its proposed trastuzumab biosimilar.

Finally, last week, our e-newsletter asked whether you think that the so-called “nocebo” effect adequately explains patients switching away from biosimilars. To view results of the poll, visit The Center for Biosimilars® on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
Ha Kung Wong, JD.
Prerakkumar Parikh, PharmD
Cencora's Corey Ford
Brian Biehn
GBW 2023 webinar
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Fran Gregory, PharmD, MBA
Julie Reed, MS
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Related Content
© 2024 MJH Life Sciences

All rights reserved.